{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:53:32Z","timestamp":1791413612811,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005405","name":"Ritsumeikan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005405","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clinthera.2025.01.019","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T15:32:56Z","timestamp":1741015976000},"page":"347-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness Analysis of SOX Plus Bevacizumab Versus SOX Plus Cetuximab for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer in Japan"],"prefix":"10.1016","volume":"47","author":[{"given":"Takashi","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Fujito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.01.019_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0002","unstructured":"National Cancer Center. Center for cancer control and information service. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2023_jp.html. Accessed February 20, 2024."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2025.01.019_bib0003","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0004","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0006","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdx738","article-title":"Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS","volume":"29","author":"Yoshino","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer. Version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01225","article-title":"Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer","volume":"38","author":"Cremolini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0010","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","article-title":"Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials","volume":"48","author":"Bokemeyer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0011","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0012","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S1470-2045(13)70490-X","article-title":"Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial","volume":"14","author":"Yamada","year":"2013","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.01.019_bib0013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s10120-003-0232-9","article-title":"S-1 in gastric cancer: a comprehensive review","volume":"6","author":"Maehara","year":"2003","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0014","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1186\/s12885-021-08690-y","article-title":"Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)","volume":"21","author":"Nishizawa","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clinthera.2022.11.009","article-title":"Cost-effectiveness analysis of monoclonal antibodies in the first-line treatment of RAS wild-type metastatic colorectal cancer: a systematic review","volume":"45","author":"Morimoto","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/COC.0000000000000231","article-title":"Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States","volume":"41","author":"Shankaran","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0017","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1080\/13696998.2019.1709848","article-title":"Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study","volume":"23","author":"Stintzing","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0018","unstructured":"US Food & Drug Administration. FDA approves new dosing regimen for cetuximab. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-new-dosing-regimen-cetuximab. Accessed February 20, 2024."},{"key":"10.1016\/j.clinthera.2025.01.019_bib0019","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jjco\/hyv182","article-title":"Bevacizumab safety in Japanese patients with colorectal cancer","volume":"46","author":"Hatake","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0020","unstructured":"Exchange Quotations \u2013 Yearly Averages. Mitsubishi UFJ Research and Consulting Co, Ltd. https:\/\/www.murc-kawasesouba.jp\/fx\/year_average.php. Accessed February 20, 2024."},{"key":"10.1016\/j.clinthera.2025.01.019_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","article-title":"Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system","volume":"23","author":"Hasegawa","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0022","unstructured":"CORE, HEALTH. Guideline for Preparing Cost-Effectiveness Evaluation to The. Central Social Insurance Medical Council Version 3.0: Center for Outcomes Research and Economic Evaluation for Health (C2H), National Institute of Public Health. Japan. Accessed February 20, 2024. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0024","unstructured":"Nice LN. DSU technical support document 14. Survival analysis for economic evaluations alongside clinical trials \u2013 extrapolation with patient level data. Decision support unit. https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD14-Survival-analysis.updated-March-2013.v2.pdf. Accessed February 20, 2024; updated March 2013."},{"key":"10.1016\/j.clinthera.2025.01.019_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12913-016-1961-x","article-title":"Cost of physician-led home visit care (Zaitaku care) compared with hospital care at the end of life in Japan","volume":"17","author":"Kinjo","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0026","series-title":"Measuring and Valuing Health Benefits for Economic Evaluation","author":"Brazier","year":"2016"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0027","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bjc.2011.409","article-title":"Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment","volume":"105","author":"Bennett","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0028","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/bjc.2011.179","article-title":"A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer","volume":"104","author":"Wang","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0029","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/hec.584","article-title":"The death of cost-minimization analysis?","volume":"10","author":"Briggs","year":"2001","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0030","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0031","unstructured":"National Cancer Center. Center for cancer control and information service. https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/hosp_c_reg_surv\/index.html. Accessed February 20, 2024."},{"key":"10.1016\/j.clinthera.2025.01.019_bib0032","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/13696998.2018.1510409","article-title":"A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US","volume":"21","author":"Graham","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2176056","article-title":"Treatment of elderly patients with colorectal cancer","volume":"2018","author":"Itatani","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0034","first-page":"715","article-title":"Title in Japanese","volume":"66","author":"Kawamoto","year":"2013","journal-title":"J Jpn Soc Colo-Proctol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oncolo\/oyab030","article-title":"Efficacy and safety of cetuximab dosing (biweekly vs weekly) in patients with KRAS wild-type metastatic colorectal cancer: a meta-analysis","volume":"27","author":"Aparna","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0036","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0037","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0038","article-title":"Cost-effectiveness of anti-epidermal growth factor receptor therapy versus bevacizumab in KRAS wild-type (WT), Pan-RAS WT, and Pan-RAS WT left-sided metastatic colorectal cancer","volume":"11","author":"Shing","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinthera.2025.01.019_bib0039","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.vhri.2021.07.001","article-title":"Cost-effectiveness of first-line cetuximab in metastatic colorectal cancer in Saudi Arabia","volume":"28","author":"Shereef","year":"2022","journal-title":"Value Health Reg Issues"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:37:16Z","timestamp":1791412636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0149291825000335"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of SOX Plus Bevacizumab Versus SOX Plus Cetuximab for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer in Japan","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}